Quantcast
Home > Quotes > NGM

NGM Biopharmaceuticals, Inc. Common Stock (NGM) Quote & Summary Data

NGM 
$14.37
*  
0.17
1.2%
Get NGM Alerts
*Delayed - data as of Jul. 17, 2019  -  Find a broker to begin trading NGM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    NGM Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
26
Today's High / Low
$ 14.5799 / $ 14.045
Share Volume
72,101
50 Day Avg. Daily Volume
95,396
Previous Close
$ 14.20
52 Week High / Low
$ 18.75 / $ 12
Market Cap
948,734,171
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
72,101
50 Day Avg. Daily Volume:
95,396

Trading Range

The current last sale of $14.37 is 19.75% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.5799 $ 18.75
 Low: $ 14.045 $ 12

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. These diseases are among the largest unmet medical needs globally and represent leading causes of morbidity and mortality and a significant burden for healthcare systems. Since the commencement of our operations in 2008, we have generated a robust portfolio of seven product candidates, five of which are in clinical testing. Our most advanced product candidate, NGM282, is wholly-owned and will enter Phase 2b development for the treatment of non-alcoholic steatohepatitis, or NASH, in mid-2019. In an ongoing Phase 2 clinical trial, NGM282 demonstrated the ability to rapidly improve NASH and reverse liver fibrosis at 12 weeks.  ... More ...  



Risk Grade

Where does NGM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.19
Open Date:
Jul. 17, 2019
Close Price:
$ 14.37
Close Date:
Jul. 17, 2019


Consensus Recommendation

Analyst Info